Tier 1

Radiopharmaceuticals made on a regular basis, relatively high volume.

On active production list.

[F-18] FDG (ANDA) imaging agent of glucose uptake, making it useful for imaging tumors.  It is the standard imaging agent used in PET for cancer patient management
[F-18] Dopa (Fluorodopamine) submitting ANDA ,EIND)  Indicated use as imaging agent of movement disorders, and brain malignancies.  It may also be useful for imaging other malignant diseases such as neuroendocrine tumors, pheochromocytoma and pancreatic adenocarcinoma.
Ga-68 NETSPOT (AAA) Commercial using Ga 68 dotatate indicate the presence and density of somatostatin receptors in tissues.
[C-11] BTA(PIB) (IND,RDRC) Indicated uses as an amyloid imaging agent
[C-11] PBR28 (RDRC) Indicated use as a TSPO binding agent used as a potential imaging agent for inflammatory processes involving macrophage activation.
[C-11] CHO (Choline) (ANDA) Imaging agent used to detect sites of prostate cancer that have returned despite treatment (recurrent prostate cancer). It may be used when other imaging has not been helpful
[C-11] Raclopride (RDRC) Indicated use as reversible imaging agent of D2/3 receptors.
[N-13] Ammonia (ANDA) Indicated use for diagnostic Posit imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.
[O-15] Oxygen (RDRC,IND) Inhalation of 0-15 labeled 02 is indicated as an imaging agent oxygen extraction.
[O-15] Water (RDRC, IND)  Indicated use as an imaging agent of blood flow. Because it is washed out in proportion to the regional blood flow and its kinetics are not affected by metabolism it can be used to assess blood flow.

Tier 2

Radiopharmaceuticals typically made occasionally, relatively low volume. On an as-needed basis with volume minimums.

One-on-one consultation with customer to determine production needs and price, or requires special approval.

[F-18] FLT(Fluorodeoxythymidine) (IND) Indicated use to image cellular proliferation, FLT is a nucleoside analog that accumulates in proliferating cells. May validate the efficacy of chemotherapy in patients with lymphoma and other cancers.
[F-18] FFNP (Fluorofurylmethylidene dioxynorpregnenedione) (IND)  Indicated use as an imaging agent that binds to progesterone receptors (PgR) in progesterone-responsive tissues. In PgR-positive breast cancer, it may be used to quantitate hormone receptor status
[F-18] ISO-1 (Sigma-1) (IND) Indicated use as a promising imaging agent for evaluation of the proliferative status of solid tumors.
[F-18] NOS (Nitric oxide synthase) (EIND) Used to evaluate the feasibility of imaging cellular iNOS activity.
[F-18] VAT Collaboration with Dr. Zhude (Will) Tu (IND)  Indicated use to quantify the vesicular acetylcholine transporters in the brain synapses in the central nervous system CNS.
[F-18] MK6240 (IND, Cerveau)  Tau imagining agent (requires special approval)
[F-18] AV1451 (IND, AVID IND)  Tau imagining agent (requires special approval)
[F-18] FES (Fluoroestradiol) (RDRC, IND) Indicated use as an imaging agent of estrogen receptor content in breast tumors.
[C-11] Palmitate (RDRC)  Palmitate is the most accurate method to measure myocardial fatty acid metabolism, permitting measurement of FA uptake, oxidation and storage
[C-11] PKAB (C-11 LY2795050) (IND)  An antagonist imaging agent for Kappa opioid  receptor
[C-11] DTBZ (Desmethyl dihydrotetrabenazine) (RDRC) Indicated use as a marker of dopaminergic terminal densities in human striatum and is expressed in islet beta cells in the pancreas
[C-11] NMB(n-methyl-benperidol) (RDRC) Indicated use as an imaging agent for D2 receptors
[C-11] S1P1 [11C] TZ3321 used assess the inflammation response that will not have genetic phenotype limitation
[F-18] FTT FluorThanatrace (Parp1 WC-4-138) (IND) An imaging agent of PAR activity that may aid in the selection of patient that will benefit from PARP inhibition treatments.
[C-11] NNC 112 (RDRC) potential of a selective D1-dopamine receptor antagonist Revalidated and submitted 2/2019

Tier 3

Radiopharmaceuticals potentially requiring start-up cost.
In-depth consultation with facility directors to determine availability for a particular project and financial feasibility is needed.
[C-11] PK1195 (RDRC)  PK 11195 is a high-affinity ligand
for the  peripheral benzodiazepine receptor (PBR)
[C-11] Glucose (RDRC) Glucose utilization imaging agent
[C-11] Leucine (RDRC) Metabolism
[C-11] Acetate (RDRC)  Myocardiol metabolism and indicated use as a tumor imaging agent in prostate cancer and
[C-11] CFT (2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane) (RDRC) Indicated use as a dopamine transporter imaging agent showing  good selectivity for the dopamine transporter over other transporters and shows  little non-specific binding in the brain
[F-18] FAA (FluorBetaOx) (EIND) Indicated use to measure  beta oxidation of fatty acids in the myocardium
[F-18] FTP (FluorTriopride-Mesylate) (IND) A dopamine D3-receptor imaging agent
[F-18] FHBG (Fluorohydroxybutylguanine)  Indicated use for imaging the expression of HSV1-tk or HSV1-sr39tk with positron emission tomography (PET) in living subjects
[F-18] NaF (animal only) approved drug  Imaging of bone abnormalities
[Cu-64] LLP2A (IND)  Imaging myeloma
[Cu-64] ATSM Imaging hypoxia
[Zr-89] Herceptin (IND) HR2+ Breast CA
Cu-64 SARTATE (Clarity) (IND) CMC completed


The Quantitative Imaging Informatics Resource (QI2R) of the PET-RTRC was established to ensure standardized evaluation of radiotracer performance and to facilitate the movement and management of data throughout the PET-RTRC.  As such, the QI2R has two primary functions: quantitative image analysis of Center image datasets and development and management of informatics pipelines.  Quantitative image analysis is a two tier-operations.  As a first tier of operation, the QI2R will provide guidance and expertise in quantitative imaging to be employed by TR&Ds.  In doing so, the QI2R will promote standardized/unified image analytics across Center activities and promote training of Center members.  As a second tier of operation, the QI2R will develop and implement advanced quantitative imaging pipelines to characterize radiotracer performance.  To facilitate the movement and management of data throughout the Center, the QI2R developed the co-clinical database (CCDB).  The CCDB is built on XNAT, a widely used open source imaging informatics platform.  XNAT is a web-based software platform designed to facilitate common management and productivity tasks for imaging and associated data.  A fine-grained access control system ensures that users are restricted to accessing only authorized data.  XNAT also includes a web services API for programmatic access and a plugin architecture for extending XNAT’s core capabilities. For QI2R, data contributors will upload Center-related data and metadata to the CCDB using a secure web application. Data will be organized in study-specific projects that provide access to authorized personnel. 


Training is available for PET radiochemists and radiopharmacists to synthesize radiotracers produced by the PET-RTRC and scientists who use this technology. We provide opportunities for interested researchers, such as basic scientists with training in preclinical imaging using PET radiotracers and clinician scientists in the design and conduct of human research studies using PET as an imaging modality.
For more information, please contact Michelle Hoelscher

Standardized Procedures

For optimal evaluation of radiotracer performance, Standardized Procedures are available upon request.